Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis

BACKGROUND: The anti–human epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab improves outcomes in patients with node-positive HER2+ early breast cancer. Given trastuzumab’s high cost, we aimed to estimate its cost-effectiveness by heterogeneity in age and estrogen receptor (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, William, Kvizhinadze, Giorgi, Nair, Nisha, Blakely, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978494/
https://www.ncbi.nlm.nih.gov/pubmed/27504960
http://dx.doi.org/10.1371/journal.pmed.1002067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978494/
https://www.ncbi.nlm.nih.gov/pubmed/27504960
http://dx.doi.org/10.1371/journal.pmed.1002067

Ejemplares similares